RT Journal Article
SR Electronic
T1 Advancing oncology with federated learning: transcending boundaries in breast, lung, and prostate cancer. A systematic review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.08.24311681
DO 10.1101/2024.08.08.24311681
A1 Ankolekar, Anshu
A1 Boie, Sebastian
A1 Abdollahyan, Maryam
A1 Gadaleta, Emanuela
A1 Hasheminasab, Seyed Alireza
A1 Yang, Guang
A1 Beauville, Charles
A1 Dikaios, Nikolaos
A1 Kastis, George Anthony
A1 Bussmann, Michael
A1 Khalid, Sara
A1 Kruger, Hagen
A1 Lambin, Philippe
A1 Papanastasiou, Giorgos
YR 2024
UL http://medrxiv.org/content/early/2024/08/09/2024.08.08.24311681.abstract
AB Federated Learning (FL) has emerged as a promising solution to address the limitations of centralised machine learning (ML) in oncology, particularly in overcoming privacy concerns and harnessing the power of diverse, multi-center data. This systematic review synthesises current knowledge on the state-of-the-art FL in oncology, focusing on breast, lung, and prostate cancer. Distinct from previous surveys, our comprehensive review critically evaluates the real-world implementation and impact of FL on cancer care, demonstrating its effectiveness in enhancing ML generalisability, performance and data privacy in clinical settings and data. We evaluated state-of-the-art advances in FL, demonstrating its growing adoption amid tightening data privacy regulations. FL outperformed centralised ML in 15 out of the 25 studies reviewed, spanning diverse ML models and clinical applications, and facilitating integration of multi-modal information for precision medicine. Despite the current challenges identified in reproducibility, standardisation and methodology across studies, the demonstrable benefits of FL in harnessing real-world data and addressing clinical needs highlight its significant potential for advancing cancer research. We propose that future research should focus on addressing these limitations and investigating further advanced FL methods, to fully harness data diversity and realise the transformative power of cutting-edge FL in cancer care.Competing Interest StatementGP, SB and HK are full-time employees of Pfizer and hold stock/stock options. CB is a full-time employee of Flower. The other authors do not have any financial or non-financial competing interests to declare.Funding StatementOPTIMA is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 101034347. IMI2 receives support from the EU Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. The views communicated within are those of OPTIMA. Neither the IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a systematic review paper hence we only analysed and evaluated published information in articles that passed our paper inclusion filters (as per the PRISMA flow).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.